OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Jerri Rook

6 Projects | 1 Researchers | $875,000 Invested

2020

Vanderbilt University

Jerri Rook, PhD

2020 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Development of mGlu5 negative or silent allosteric modulators for the treatment of Alzheimer’s disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active

2015

Vanderbilt University

Jerri Rook, PhD

Preclinical Development of novel M1 PAMs- Year 2

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2015

Vanderbilt University

Jerri Rook, PhD

mGlu5 PAMs for the treatment of Alzheimer's disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2014

Vanderbilt University

Jerri Rook, PhD

Preclinical Development of novel M1 PAMs for the treatment of Alzheimer's disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2013

Vanderbilt University

Jerri Rook, PhD

In Vivo Characterization of Novel mGlu5 PAMs in Aged Rats

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2011

Vanderbilt University

Jerri Rook, PhD

In Vivo Characterization of Novel mGlu5 PAMs in Aged Rats

  • Funding Amount: $125,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed